Ildong Bioscience Participates in Japan's "Health Food Ingredients Expo"

Highlighting Probiotic Ingredients, ODM, and CDMO Capabilities

Ildong Bioscience, a company specializing in health functional foods under the Ildong Pharmaceutical Group, announced on the 20th that it participated in the Japan Health Food Ingredients Expo "Hi (Health ingredients) Japan 2025" to promote its functional ingredients and seek new business opportunities.

Ildong Bioscience, a company specializing in health functional food business under Ildong Pharmaceutical Group, is showcasing its business capabilities at a booth at the Japan Health Food Ingredients Expo "Hi (Health Ingredients) Japan 2025," held from the 15th to the 17th of this month. Ildong Pharmaceutical

"Hi Japan" is the largest exhibition in Japan covering ingredients and materials in the healthcare sector, including health foods and functional products. This year's event was held at the Tokyo Big Sight Exhibition Center from the 15th to the 17th, with participation from more than 650 companies from various countries.

At this event, Ildong Bioscience not only highlighted its functional ingredients and materials utilizing various proprietary probiotic strains, but also showcased its core technologies such as the quadruple coating process, as well as its capabilities in Contract Development and Manufacturing Organization (CDMO) and Original Design Manufacturing (ODM) businesses.

The company explained that it drew particular attention by introducing "PPP Probiotics," which contain not only live probiotics that are beneficial to health, but also prebiotics and postbiotics that interact with probiotics.

Prebiotics are substances that help the proliferation and activation of beneficial microorganisms in the gut, while postbiotics refer to beneficial metabolic byproducts produced by probiotics such as lactic acid bacteria.

In addition to "PPP Probiotics," the company also received a positive response by introducing "Clostridium butyricum IDCC 1301," a butyric acid bacteria strain from Ildong Pharmaceutical Group's "Biovita strains," targeting the Japanese market where butyric acid bacteria are in high demand.

The company emphasized that "Clostridium butyricum IDCC 1301" holds numerous research data and patents related to inflammatory bowel disease, forms its own protective barrier to safely reach the intestines, and demonstrates excellent heat resistance, surviving at temperatures up to 90 degrees Celsius, which provides a strong business advantage.

An Ildong Bioscience representative stated, "We are accelerating our entry into the global market by focusing on functional ingredients related to irritable bowel syndrome, reduction of blood cholesterol, reduction of body fat, and skin immunity. At the same time, we plan to continuously develop differentiated ingredients and products by leveraging our technological expertise in probiotics and postbiotics."

This content was produced with the assistance of AI translation services.